Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease

Le Shu 1,2, Montgomery Blencowe 1 and Xia Yang 1,2,3,4,5*

1 Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, United States, 2 Molecular, Cellular, and Integrative Physiology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, United States, 3 Bioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, United States, 4 Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, Los Angeles, CA, United States, 5 Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, United States

The success of genome-wide association studies (GWAS) has significantly advanced our understanding of the etiology of coronary artery disease (CAD) and opens new opportunities to reinvigorate the stalling CAD drug development. However, there exists remarkable disconnection between the CAD GWAS findings and commercialized drugs. While this could implicate major untapped translational and therapeutic potentials in CAD GWAS, it also brings forward extensive technical challenges. In this review we summarize the motivation to leverage GWAS for drug discovery, outline the critical bottlenecks in the field, and highlight several promising strategies such as functional genomics and network-based approaches to enhance the translational value of CAD GWAS findings in driving novel therapeutics.

Keywords: genome-wide association study, coronary artery disease, drug targets, multi-omics, functional genomics, networks

INTRODUCTION

Coronary artery disease (CAD) is a leading cause of mortality worldwide (1). CAD is well recognized as a complex disease with both genetic and environmental contributions (2). The heritability of CAD is estimated to be 40–50% (3), and the genetics of CAD plays an indispensable role in unraveling the pathogenic processes and ultimately facilitating the discovery of novel therapeutics. In the past decade, our understanding of the genetic architecture and mechanistic underpinnings for CAD has been substantially accelerated and broadened, primarily attributable to the successful global collaborative efforts in large-scale human genome-wide association studies (GWAS). These efforts have helped reveal hundreds of novel genetic variants demonstrating significant associations with CAD.

In contrast to the gratifying successes of GWAS, the development of CAD drugs has stagnated over the past decades, especially when compared to other therapeutic areas (4). What is particularly concerning is the fact that the drug development effort has been primarily concentrated on correcting previously established CAD risk factors such as lipid levels, coagulation factors, and hypertension, instead of targeting novel pathways revealed from recent studies (Figure 1). This decoupling between mechanistic discovery studies and drug development is striking. Therefore, it is of critical importance to form strategies that leverage the recent genetic discoveries from GWAS and other relevant efforts such as multi-dimensional data integration and systems genetics to allow for efficient identification of novel and reliable CAD drug targets. In this review, we summarize the state of CAD GWAS.
discovery, delineate the significant challenges of translating GWAS to drug targets, discuss successful examples of GWAS driven CAD drug target discovery, and outline promising strategies to further catalyze the translation of CAD GWAS into novel therapeutic options.

**GWAS DISCOVERY FOR CAD AND ITS IMPLICATIONS FOR DRUG TARGET DISCOVERY**

The completion of the human genome project, the rapid declining cost of genome sequencing, the rising feasibility of global multi-group collaborations, and the increasing accessibility of shared data repositories have collectively fueled the explosion of genetic studies of CAD, particularly GWAS. GWAS were typically designed to profile common known variants, often defined as variants with allele frequency ≥ 0.5% (5), on pre-designed microarrays containing primarily single nucleotide polymorphisms (SNPs). Since the first CAD GWAS in 2007 (6), over 18 GWAS studies have been carried out in the past decade, with the most recent and largest study involving 34,541 cases and 261,984 controls (7). These studies revealed a total of 163 genetic loci linked to CAD (8) (Figure 1), explaining 30–40% of CAD heritability (7, 9, 10).

Overall, GWAS have played a key role in not only confirming classic CAD risk factors such as LDL cholesterol, hypertension, and coagulation, but also highlighting the causal roles of cellular proliferation and adhesion, extracellular matrix, and inflammation (Figure 1), which are processes related to the endothelial and smooth muscle cells in the vascular wall and the immune system (3, 11). Unfortunately, to date no novel CAD GWAS genes beyond a few involved in classic risk factors have been established as viable drug targets for CAD, a pattern that resonates for GWAS of most complex traits (Figure 1) (12). The disconnection between CAD GWAS findings and treatment targets is disappointing and has been criticized, but could also implicate major untapped opportunities (13). In particular, the causal variants and genes involved in the new causal pathways informed by GWAS have been encouraging early stage advances in uncovering novel therapeutic options targeting the vascular wall components, cell proliferation, and inflammation. For example, the ADAMTS7 loci, coding for a metalloproteinase with thrombospondin motifs 7, was implicated for atherosclerotic progression through smooth muscle cell migration, a mechanism independent of classic CAD risk factors (14). Upon confirmation of its causal role in affecting atherosclerosis occurrence in vivo (15), development of the ADAMTS7 pharmacophore has progressed towards establishing inhibitors via virtual screening (16).
Tocilizumab, an anti-inflammatory agent blocking interleukin-6, was found to improve endothelial function (17). Antibodies targeting CD47, a key anti-phagocytic and tumorigenic molecule, were also shown to ameliorate atherosclerosis by stimulating efferocytosis (18).

Despite the potential promises, several factors could have complicated the extraction of therapeutic value from GWAS. First, the functional regulatory circuits from most variants to disease outcomes remain elusive. This is reflected by both the difficulty in pinpointing the causal variants and the corresponding target genes, especially for variants located in non-coding regions. In fact, the exact effector genes and functions for over 50% of the CAD GWAS loci are unclear. For example, the 9p21 locus was the strongest CAD locus but is located in a gene desert (6, 19, 20). Multiple follow-up studies have suggested several effectors for this locus, including the non-coding RNA ANRIL (21), CDKN2A/CDKN2B (22, 23), and interferon-gamma signaling (24). However, the detailed mechanism is still under debate after a decade of research (25). Moreover, even if a CAD variant is located within a gene-rich region, the most adjacent gene(s) may not be the functional candidate (26). Second, even if the candidate genes can be unequivocally determined, the functions of the genes are not necessarily well established, and extensive functional studies are required to derive a mechanistic understanding of how the candidate genes lead to CAD risks. Third, most common variants only confer weak to moderate CAD risk (<20% change in risk), most likely due to evolutionary pressure which selects against non-synonymous SNPs in disease genes involved in key physiological processes (12, 27–30). The prevalence of moderate/weak effect sizes of CAD risk variants makes prioritization of drug targets difficult. Lastly, it has been suspected that the top CAD risk variants identified so far predominantly inform on genes active in the early and slow phase of CAD development, whereas variants affecting late and rapid CAD phases tend to be missed by GWAS as these are likely more dependent on specific contexts such as particular environmental exposures or inflammatory states that are poorly controlled in most GWAS (31). Indeed, a recent study of Crohn's disease that focuses on disease course or prognosis using a within-cases design revealed loci that are completely different from those derived from case-control studies (32). This is also likely the case for CAD. Therefore, drug targets derived from CAD GWAS findings may not carry the expected efficacy to counteract CAD progression.

**STRATEGIES TO FAST-FORWARD THE TRANSLATION OF GWAS TO TREATMENT TARGETS**

To bypass the challenges facing the translation of GWAS findings to therapeutic targets as outlined above, a number of strategies have been designed and attempted. These efforts mainly focus on integrating GWAS hits with other data types that help inform on the functions of candidate genes, pathways, and networks, narrow down and prioritize the causal candidates, and leverage the matching patterns between disease mechanisms and molecular patterns of drugs (Figure 2).

**Use of Rare Variant Association Studies to Prioritize Targets**

As discussed above, common variants uncovered from GWAS studies are numerous in number while carrying weak to subtle effect sizes, making it challenging to prioritize viable targets. Rare genetic variants (frequencies lower than 0.5%) that are associated with diseases, on the other hand, usually exhibit stronger perturbations in gene functions and are under stronger evolutionary pressure. Therefore, rare variants, especially those leading to loss-of-function, provide a natural setting mimicking human knockout cases to assess phenotypic and clinical consequences of variants, and their power in informing causal disease genes and drug targets has been long recognized (Figure 2A) (33, 34). Aggregation of rare mutations in 10 genes, including APOA5 (35), APOC3 (36), ADRB1 (37), ANGPTL3 (38), ANGPTL4 (39), LPA (40), LDLR (35), LPL (41), NPC1L1 (42), and PCSK9 (43), has been linked to CAD risk through whole exome or whole genome sequencing-based studies. Out of the 10 genes, 5 (ANGPTL4, APOC3, LPA, NPC1L1, PCSK9) have been explored as drug targets for CAD (3). To date, the main success of this approach lies in the approval of PCSK9 antibodies by the FDA. Carriers with inactivating mutations on PCSK9 were found to have markedly lower LDL cholesterol level and CAD risk, which led to the discovery of two FDA-approved monoclonal antibodies, Alirocumab and Evolucumab. However, the potential of drug discovery using CAD rare variants is also limited by both the small number of robust rare variants found so far, and their low cumulative contribution to CAD risk in the general population (9). Additionally, most of them are involved in the previously established pathways rather than novel mechanisms. Nevertheless, these rare variants provide compelling causal inference of the downstream genes and pathways in CAD pathogenesis, and they are more likely to be specific to a disease (broad effects could be detrimental in human knockouts) and have safer profiles, key components for success as drug targets. Future GWAS will likely evolve from SNP array design to whole genome sequencing to profile both common and rare variants (44), thus further expanding the pool of loss-of-function variants for drug target selection. Some of the novel rare variants may inform on novel causal mechanisms not captured by common variants, or converge on genes and pathways already informed by common variants thus serving to enhance the causal inference at a more functional level.

**Functional Genomics to Identify and Prioritize Causal GWAS Genes**

In contrast to rare coding mutations whose target genes and downstream mechanisms can be more readily uncovered through traditional functional studies, identifying the causal genes that are responsible for the observed link between GWAS risk variants and CAD is not an easy task. It is estimated that two thirds of the predicted target genes of GWAS locus are not the closest by proximity (45, 46), thus traditional proximity-
Figure 2 | Strategies to translate CAD GWAS into drug targets. (A) Identification of CAD causal genes as candidate drug targets by incorporating functional genomics, rare variants and Mendelian randomization. Loss-of-function rare variants can be linked to downstream genes. The connection between common variants and causal genes usually requires integration of functional genomics data. Mendelian randomization can further filter the drug target selection pool by incorporating causal intermediate traits. (B) A “target-less” approach to reposition existing drug compounds for CAD by evaluating the existence of opposite patterns between drug molecular profiles and GWAS imputed molecular profiles of disease. (C) Network-based approaches that model CAD GWAS data along with other omics data from CAD relevant tissues or cell types in the context of gene networks, which have the power to pinpoint key network regulators as candidate drug targets with more potent effects.
GWAS to Therapeutics for Coronary Artery Disease

Mendelian Randomization (MR) to Facilitate Drug Target Selection

Previous successes in drug development for CAD have testified to the effectiveness of modulating intermediate causal risk factors such as circulating cholesterol levels and blood pressure in lowering CAD risk. Therefore, knowing the causal relationship between an intermediate phenotype that correlates with CAD status is of monumental importance as it can help prioritize biomarkers as intervention targets for CAD therapeutics (58, 59) (Figure 2A). The investigation of causal intermediate traits for CAD can be facilitated by MR, which utilizes genetic variants as instrumental variables to assess the causal relationship between exposure (e.g., LDL cholesterol, HDL cholesterol, weight-hip ratio) and outcome (CAD occurrence) (60). We are seeing both successful and ongoing efforts in developing drugs modulating LDL cholesterol, triglyceride-rich lipoproteins and lipoprotein (a) (3), whose causal relationships with CAD have been robustly verified in MR studies (61–63). On the contrary, MR studies revealed inconsistent relationship between HDL cholesterol and CAD (64–66). In concordance with this lack of robust support for the causality of HDL in CAD, substantial obstacles have been met during the development of inhibitors for CETP (cholesteryl ester transfer protein), a gene harboring several loci associated with HDL cholesterol level (67). Three commercial CETP inhibitors, Dalcetrapib, Obicetrapib and Anacetrapib, all failed to achieve clinical efficacy during phase III clinical trials and were discontinued (68).

In addition to the well explored causal pathways such as cholesterol and blood pressure regulation, MR studies have informed several additional causal intermediate phenotypes, such as inflammation (69), uric acid (70), and iron status (71), that could serve as targets for future CAD drug development. By utilizing both summary-level GWAS statistics and UK Biobank data, a recent MR study demonstrated the causal association of waist-to-hip ratio adjusted for body mass index with coronary heart disease, thus providing new opportunities of intervening CAD risk by reducing abdominal obesity (72).

GWAS-Based “Target-Free” Drug Repositioning

Drug repurposing approaches could leverage known drugs used for other diseases that target the newly uncovered CAD causal genes and pathways to counteract CAD. For example, better understanding of CAD pathways involved in inflammation and cell cycle has promoted the repurposing of drugs targeting diseases such as rheumatoid arthritis (17) and cancer (18). On the other hand, given the challenging nature of identifying both the causal genes from GWAS and matching it with the target of drug compounds, “target-free” approaches have been developed which require no prior knowledge of targets for either drugs or GWAS variants and can simultaneously take many genetic loci into consideration (73) (Figure 2B). The fundamental concept behind these approaches is to impute gene expression profiles from GWAS summary statistics, compare the expression patterns against gene expression profiles of drugs, then prioritize top drug candidates whose profiles show reverse patterns compared with GWAS-imputed signatures. This approach is especially useful for repositioning existing drugs whose chemical properties and molecular responses have been well characterized and made accessible from public data repositories such as CMap (74) and its successor, the L1000 platform (75), as well as other chemoinformatic resources (76, 77).

To facilitate such efforts, the work by Gamazon et al. represents one of the first transcriptome imputation pipelines where disease relevant gene expression is estimated from a tissue-dependent model trained with personal genotype data and reference transcriptome (78). Gusev et al. and So et al. further developed summary GWAS statistics based transcriptome imputation methods, which relieved the requirement for individual genotype data (73, 79). In addition, inferring gene expression changes from GWAS enables researchers to assess transcriptome-wide associations with CAD that could yield novel candidate genes for functional and therapeutic investigation (45, 79). Although direct application of the “target-free” approaches for CAD is still under-explored, a computational framework has been developed to reposition existing drugs for psychiatry (73). The framework, built on a GWAS-based transcriptome imputation pipeline named MetaXcan (80), first imputed the gene expression...
profiles of 10 brain regions for 7 psychiatric disorders based on GWAS and reference transcriptome data from GTEx (55). This disease transcriptome information was then used to match with drug-induced gene expression profiles from the CMap database (74) to prioritize drugs that showed opposite gene expression patterns compared to the disease patterns. These platforms are potentially translatable to CAD.

Network-Based Drug Discovery Approaches
The success of GWAS-driven drug target identification heavily relies on the fundamental assumption of how genetic risk variants eventually contribute to disease phenotype. An “omnigenic” model for the genetics of complex traits has been recently proposed (30). This provocative model objects the common belief that risk variants drive disease etiology through functional clustering in biological pathways, and emphasizes that all genes in disease-relevant cells could affect core disease processes through the coordination of gene regulatory networks.

Motivated by the gene network hypothesis, the CAD field has been actively investing on the development and application of systems genetics frameworks that integrate genetics and other data dimensions in the context of network topology to help prioritize candidate CAD genes (Figure 2C) (27–29, 81–84). The implementation of network-based target identification strategies poses several unique advantages over other methods. First, gene networks have the potential to comprehensively map the regulatory circuits under physiological or pathological conditions, thus improving the biological relevance of predicted targets. Second, gene networks serve as a natural platform for data integration, where GWAS and information from other omics space can be collectively leveraged to pinpoint network hotspots where key perturbation events likely happen. Third, gene networks enable the identification of essential disease genes, which is unlikely to tolerate high frequency loss-of-function variation at the population level and to be discovered by GWAS (85). Several methods have been developed to find network essential genes, or key drivers, by considering both network topology and external disease signatures (27, 81, 86). The validity of the predicted key drivers in driving CAD relevant traits has been well supported (27, 29, 82), and the key drivers have the potential to serve as novel drug targets with strong therapeutic effects due to their central importance in regulating the disease networks. For instance, Zhao et al. recently prioritized CAD key drivers and proposed plausible targets using network approaches (28). Extensive in vitro and in vivo gene perturbation experiments are required to evaluate the feasibility of using key driver genes as drug targets. If proven valid, network-based discoveries could provide exciting opportunities to formulate more focused and data-informed hypotheses for downstream therapeutic investigation. Nevertheless, it is important to caution that modulation of network key drivers may result in a lack of specificity and increase the risks for side effects due to their broad impact on numerous network genes.

One critical challenge for network-based CAD drug discovery is the availability of high-quality gene networks from CAD relevant cells, tissues, and subjects. Many existing networks are literature-based and lack tissue/cell specificity. Even for data-driven networks, data collection bias exists. For example, human network construction usually requires large numbers of clinical samples that are difficult to acquire, especially for samples from internal tissues. A major breakthrough is the establishment of the STARNET networks involving tissue-specific data from ~600 CAD patients (87). This resource, in combination with other networks generated from mouse models or non-disease human subjects, is invaluable for future CAD network studies. Coordinated efforts by the research community are needed to enhance the coverage of data-driven networks from CAD relevant tissues and cell types.

CONCLUSIONS AND FUTURE DIRECTIONS
GWAS has been highly successful in elucidating the genetic architecture of CAD and driving the discovery of novel biology. While confirming the genes and pathways targeted by classic CAD treatments, GWAS opens doors to a vast number of under-recognized candidates where future CAD drugs could originate. The field of GWAS-driven drug discovery is still at its infancy, and significant challenges remain. However, it is encouraging that numerous methodological advances have been made to address the bottlenecks, and application of these approaches is expected to facilitate future translational research in CAD.

Here we anticipate the following future directions that will help further advance the field. First, there is a need for broader collaboration to conduct large-scale functional genomics studies in human tissues and cell types that implement cutting-edge high-throughput profiling technologies over multiple omics to map the tissue- and cell-type specific regulatory circuit of GWAS loci. In particular, application of cell-type specific analyses at multi-omics levels will help address the functional heterogeneity in CAD relevant tissues, which will lead to refined understanding of disease etiology and lay a solid foundation for more accurate prediction of drugs that can counteract the specific pathogenic processes in the right cell types and tissues (88). The recent launch of the Human Cell Atlas project represents one of the first stepping stones towards this direction (89). Second, more efficient platforms are needed to facilitate sharing of summary-level GWAS data as well as databases and data repositories that curate multi-omics functional information. For example, in the neurological disorder field, there are emerging efforts like CommonMind (http://commonmind.org), PsychENCODE (90) and BrainSeq (91). Similar coordinated efforts by the CAD community will accelerate identification of CAD drug targets. Third, the translational value of GWAS data can be better exploited by the development of novel analytical pipelines that integrate multi-dimensional data from animals, humans, and chemoinformatic databases. Some of the recently developed analytical pipelines can integrate GWAS and functional genomics data for target prediction, and are directly applicable to CAD.
Additional pipelines that couple disease datasets with drug footprints in a gene network framework will facilitate the identification of network regulators and pathways that can be accurately targeted. Lastly, gradual transition from initial target screening to GWAS-guided experimental validation of the predicted targets using a combination of in vitro, in vivo, and in silico methods will further the translational path.

AUTHOR CONTRIBUTIONS

LS, MB and XY drafted and edited the manuscript.

REFERENCES

1. Abubakar I, Tillmann T, Global BA. Regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 385(9963):117–71.
2. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med (2016) 375(24):2349–58. doi: 10.1056/NEJMoa1605086
3. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet (2017) 18(6):331–44. doi: 10.1038/nrg.2016.160
4. Fordyc CB, Roe MT, Ahmad T, Libby P, Hiatt WR, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol (2015) 65(15):1567–82.
5. Zuck O, Schaffner SE, Samocha K, do R, Hechter E, Kathiresan S, et al. Searching for missing heritability: Designing rare variant association studies. Proc Natl Acad Sci USA (2014) 111(4):E455–64. doi: 10.1073/pnas.1322563111
6. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Lancet (2007) 447(7145):661–78. doi: 10.1016/S0140-6736(07)60205-7.
7. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease novelty and significance. Circ Res (2018) 122(3):433–43. doi: 10.1161/CIRCRESAHA.117.312086
8. Erdmann J, Kessler T, Munoz Venegas L, Schunkert H. A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res (2018) 385. doi: 10.1093/cvr/cvy084
9. Nikolau M, Koel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet (2015) 47(10):1211–30. doi: 10.1038/ng.3396
10. Klarin D, Zhu QM, Emdin CA, Chaffin M, Horner S, McMillan BJ, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet (2017) 49(9):1392–7. doi: 10.1038/ng.3914
11. Kessler T, Vilne B, Schunkert H. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med (2016) 8(7):688–701. doi: 10.15252/emmm.201506174
12. Cao C, Moult J. GWAS and drug targets. BMC Genomics (2014) 15(Suppl 4):SS. doi: 10.1186/1471-2164-15-S4-S5
13. Schooling CM, Huang JV, Zhao JV, Kwok MK, Yeung SL, Lin SL. Disconnect between genes associated with ischemic heart disease and targets of ischemic heart disease treatments. Elife (2018) 28311–5. doi: 10.1016/j.ebiom.2018.01.015
14. Reilly MP, Li M, He J, Ferguson JJ, Stylianou IM, Mehta NN, et al. Identification of ADAMTS7 as a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation (2015) 131(13):1202–13. doi: 10.1161/CIRCULATIONAHA.114.012669
15. Müller M, Kessler T, Schunkert H, Erdmann J, Tenstedt S. Classification of ADAMTS binding sites: The first step toward selective ADAMTS7 inhibitors. Biochem Biophys Res Commun (2016) 471(3):380–5. doi: 10.1016/j.bbrc.2016.02.025
16. Bacchis BA, Bacchis AB, Usnao MJ, Bedirian R, Singh G, Pinheiro GDarc. Interleukin 6 Inhibition and coronary artery disease in a high-risk population: A prospective community-based clinical study. J Am Heart Assoc (2017) 6(3):e005038. doi: 10.1161/JAHA.116.005038
17. Kojima Y, Volkmann J-P, McKenna K, Civelek M, Lusis AJ, Miller CL, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature (2016) 536(7614):86–90. doi: 10.1038/nature18935
18. Heldgott D, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 316(5830):1491–3. doi: 10.1126/science.1142842
19. Mpherson R, Pertsemidlis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 316(5830):1488–91. doi: 10.1126/science.1142447
20. Holdt LM, Stahringer A, Siss K, Pichter G, Kukal NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun (2016) 7:12429. doi: 10.1038/ncomms12429
21. Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancerio H, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest (2014) 124(3):1083–97. doi: 10.1172/JCI70391
22. Kim JB, Deluna A, Mungrue IN, Vu C, Poulard D, Civelek M, et al. Effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice. Circulation (2012) 126(15):1896–906. doi: 10.1161/CIRCULATIONAHA.111.064881
23. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21.3 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 470(7333):264–8. doi: 10.1038/nature09753
24. Pjanic M, Miller CL, Wirka R, Kim JB, Direnzo MM, Quertermous T. Genetics and genomics of coronary artery disease. Circ Res (2012) 110(13):1202–13. doi: 10.1161/CIRCRESAHA.111.064881
25. Kojima Y, Usnayo MJG, Bedirian R, Singh G, Kostman E, Dirnhofer S, et al. Integrative system biology reveals novel molecular pathways and gene networks for coronary artery disease loci. Circ Res (2014) 51(5):928–41. doi: 10.1161/CIRCRESAHA.115.306725

ACKNOWLEDGMENTS

The authors thank the reviewers for the constructive comments.

FUNDING

LS is funded by the Burroughs Wellcome Fund Inter-school Training Program in Chronic Diseases Scholarship and UCLA Dissertation Year Fellowship. XY is funded by the Leducq Transatlantic Network of Excellence, NIH/NIDDK DK104363, and NIH/NINDS NS103088.
33. Macarthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, Emdin CA, Khera AV, Natarajan P, Klarin D, Won H-H, Peloso GM, et al. Myocardial Infarction Genetics, CARDIoGRAM Exome Consortium.

39. Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function ANGPTL3 deficiency and protection against coronary artery disease. N Engl J Med (2016) 374(12):1134–41. doi: 10.1056/NEJMoa1600015.

45. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integrative analysis of 111 reference human epigenomes. Nature (2015) 518(7539):317–30. doi: 10.1038/nature14248.

51. Miller CL, Panic M, Wang T, Nguyen T, Cohain A, Lee JD, et al. Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. Nat Commun (2016) 7:12092. doi: 10.1038/ncomms12092.

57. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in cardiovascular disease: a note of orthogonalization of therapeutic targets for cardiovascular disease prevention: a note of caution. Circ Res (2017) 122(1):106–12. doi: 10.1161/CIRCRESAHA.117.311978.

60. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges. PLoS Genet (2017) 13(10):e1006944. doi: 10.1371/journal.pgen.1006944.

62. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2014) 371(22):2072–82. doi: 10.1056/NEJMoa1405386.

67. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov (2014) 13(6):445–64. doi: 10.1038/nrd4279.

69. Rosenson RS, Koenig W. Mendelian randomization analyses for selection of therapeutic targets for cardiovascular disease prevention: a note of caution. Circ Res (2018) 122(1):106–12. doi: 10.1161/CIRCRESAHA.117.311978.
circumspersion. *Cardiovasc Drugs Ther* (2016) 30(1):65–74. doi: 10.1007/s10557-016-6642-9

70. Kleber ME, Delgado G, Grammer TB, Silbernagel G, Huang J, Kramer BK, et al. Uric acid and cardiovascular events: a mendelian randomization study. *Clin J Am Soc Nephrol* (2015) 10(11):2082–9. doi: 10.2215/CJN.03810315

71. Gill D, del Greco ME, Walker AP, Srai SKS, Laffan MA, Minelli C. The effect of iron status on risk of coronary artery disease: a mendelian randomization study-brief report. *Arterioscler Thromb Vasc Biol* (2017) 37(9):1788–92.

72. Emdin CA, Khera AV, Natarajan P, Klarin D, Zekavat SM, Hsiao AJ, et al. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. *JAMA* (2017) 317(6):626–34. doi: 10.1001/jama.2016.21042

73. So HC, Chau CK, Chiu WT, Ho KS, Lo CP, Yim SH, et al. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. *Nat Neurosci* (2017) 20(10):1342–9. doi: 10.1038/nn.4618

74. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* (2006) 313(5795):1929–35. doi: 10.1126/science.1132939

75. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. *Cell* (2017) 171(6):e1437–52. doi: 10.1016/j.cell.2017.10.049

76. Breen G, Li Q, Roth BL, O’Donnell P, Didriksen M, Dolmetsch R, et al. Translating genome-wide association findings into new therapeutics for neurodegeneration. *Front Pharmacol* (2017) 8:896. doi: 10.3389/fphar.2017.00896

77. Pritchard J-L, O’Mara TA, Glubb DM. Enhancing the promise of drug repositioning through genetics. *Front Pharmacol* (2017) 8:95. doi: 10.3389/fphar.2017.00095

78. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* (2015) 47(9):1091–8. doi: 10.1038/ng.3367

79. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative genetics analysis of genome-wide association studies reveals novel associations between key biological processes and coronary artery disease. *Arterioscler Thromb Vasc Biol* (2015) 35(7):1712–22. doi: 10.1161/ATVBAHA.115.305513

80. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The Human Cell Atlas. *eLife* (2017) 6. doi: 10.7554/eLife.27041

81. Franzen O, Ermel R, Cohain A, Akers NK, di Narzo A, Talukdar HA, et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. *Science* (2016) 353(6301):827–30. doi: 10.1126/science.aad6970

82. Heath JR, Ribas A, Mishel PS. Single-cell analysis tools for drug discovery and development. *Nat Rev Drug Discov* (2016) 15(3):204–16. doi: 10.1038/nrd.2015.16

83. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The Human Cell Atlas. *Nat Cell Biol* (2016) 18(12):1707–12. doi: 10.1038/nn.4156

84. Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al. The PsychENCODE project. *Nat Neurosci* (2015) 18(12):1707–12. doi: 10.1038/nn.4156

85. Bartha I, di Iulio J, Venter JC, Telenti A. Human gene essentiality. *Nat Genet* (2015) 47(9):1091–8. doi: 10.1038/ng.3367

86. Talukdar HA, ForoughiAzl H, Jain RK, Ermel R, Ruusalepp A, Fränzén O, et al. Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease. *Cell Syst* (2016) 2(3):196–208. doi: 10.1016/j.cels.2016.02.002

87. Franzen O, Ermel R, Cohain A, Akers NK, di Narzo A, Talukdar HA, et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. *Science* (2016) 353(6301):827–30. doi: 10.1126/science.aad6970

88. Heath JR, Ribas A, Mishel PS. Single-cell analysis tools for drug discovery and development. *Nat Rev Drug Discov* (2016) 15(3):204–16. doi: 10.1038/nrd.2015.16

89. Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al. The PsychENCODE project. *Nat Neurosci* (2015) 18(12):1707–12. doi: 10.1038/nn.4156

90. Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al. The PsychENCODE project. *Nat Neurosci* (2015) 18(12):1707–12. doi: 10.1038/nn.4156

91. Talukdar HA, ForoughiAzl H, Jain RK, Ermel R, Ruusalepp A, Fränzén O, et al. Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease. *Cell Syst* (2016) 2(3):196–208. doi: 10.1016/j.cels.2016.02.002

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Shu, Blencowe and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.